초록 ▼

Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): o

Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein, L, R1; R2, Z, X, A and B are defined herein.

대표청구항 ▼

1. A method of treating a diabetic condition selected from the group consisting of type 2 diabetes mellitus and a complication of type 2 diabetes mellitus in a subject, comprising administering systemically and transdermally to the subject a therapeutically effective amount of a compound selected fr

1. A method of treating a diabetic condition selected from the group consisting of type 2 diabetes mellitus and a complication of type 2 diabetes mellitus in a subject, comprising administering systemically and transdermally to the subject a therapeutically effective amount of a compound selected from the group consisting of: 2. The method of claim 1, wherein the diabetic condition is type 2 diabetes mellitus. 3. The method of claim 1, wherein the method improves glucose tolerance. 4. The method of claim 1, wherein the method reduces serum glucose. 5. The method of claim 1, wherein the method reduces glycated hemoglobin. 6. The method of claim 1, wherein the method reduces the subject's need for insulin. 7. The method of claim 1, wherein the method treats a complication of type 2 diabetes mellitus in the subject. 8. The method of claim 7, wherein the complication of type 2 diabetes mellitus is selected from the group consisting of nephropathy, peripheral neuropathy, retinopathy, atherosclerosis, stroke, myocardial ischemia, infection, foot ulcers, acidosis, and coma. 9. The method of claim 1, wherein the compound is administered to the skin at a dose of between about 3 mg in a 24-hour period to about 50 mg in a 24-hour period, inclusive. 10. The method of claim 1, wherein the peak serum concentration of the compound or active metabolite thereof is between about 50 pg/ml and 1000 pg/ml.